12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bedoradrine: Completed Phase II enrollment

MediciNova completed enrollment of 176 patients in a double-blind, placebo-controlled, U.S. Phase II (MN-221-CL-007) trial evaluating 1,200 µg IV MN-221. The company has exclusive, ex-Japanese rights to MN-221 from Kissei....

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >